Image
Get started
Image
NOW APPROVED
Introducing VYKAT™ XR - the first and only treatment
for hyperphagia in adults and pediatric patients 4 years
of age and older with Prader-Willi syndrome (PWS). 1,2
Image
Image
IMPORTANT SAFETY INFORMATION
Contraindication
Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
Warnings and Precautions
Hyperglycemia
Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.
Risk of Fluid Overload
Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
Adverse Reactions
The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.
Drug Interactions
Concomitant use of VYKAT XR with strong CYP1A2 inhibitors increases exposure of diazoxide. Reduce VYKAT XR dosage with strong CYP1A2 inhibitors. Concomitant use of VYKAT XR is not recommended with CYP1A2 substrates due to increased exposure of these substrates.
Concomitant use of VYKAT XR is not recommended with dual strong CYP3A4/moderate CYP1A2 inducers due to decreased exposure of VYKAT XR. Diazoxide is highly bound to serum proteins and may displace other drugs that are also highly bound to protein of which impact is expected to be clinically important for narrow therapeutic index drugs; monitor INR with coumarin or its derivatives and monitor diphenylhydantoin serum levels and adjust dose if needed when used concomitantly with VYKAT XR. Concomitant use of VYKAT XR with thiazides or other diuretics may potentiate hyperglycemic and hyperuricemic effects; dose adjustment of VYKAT XR or diuretics may be needed.
Please see the accompanying full Prescribing Information, including Medication Guide.
References:
- Soleno Therapeutics announces U.S. FDA approval of VYKAT™ XR to treat hyperphagia in Prader-Willi syndrome. News Release. Soleno Therapeutics. March 26, 2025. Accessed March 26, 2025. https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-us-fda-approval-vykattm-xr-treat
INDICATION
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).
IMPORTANT SAFETY INFORMATION
Contraindication
Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
Warnings and Precautions
Hyperglycemia
Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.
Risk of Fluid Overload
Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
Adverse Reactions
The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.
Drug Interactions
Concomitant use of VYKAT XR with strong CYP1A2 inhibitors increases exposure of diazoxide. Reduce VYKAT XR dosage with strong CYP1A2 inhibitors. Concomitant use of VYKAT XR is not recommended with CYP1A2 substrates due to increased exposure of these substrates.
Concomitant use of VYKAT XR is not recommended with dual strong CYP3A4/moderate CYP1A2 inducers due to decreased exposure of VYKAT XR. Diazoxide is highly bound to serum proteins and may displace other drugs that are also highly bound to protein of which impact is expected to be clinically important for narrow therapeutic index drugs; monitor INR with coumarin or its derivatives and monitor diphenylhydantoin serum levels and adjust dose if needed when used concomitantly with VYKAT XR. Concomitant use of VYKAT XR with thiazides or other diuretics may potentiate hyperglycemic and hyperuricemic effects; dose adjustment of VYKAT XR or diuretics may be needed.
Please see the accompanying full Prescribing Information, including Medication Guide.
References:
- Soleno Therapeutics announces U.S. FDA approval of VYKAT™ XR to treat hyperphagia in Prader-Willi syndrome. News Release. Soleno Therapeutics. March 26, 2025. Accessed March 26, 2025. https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-us-fda-approval-vykattm-xr-treat
INDICATION
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).